PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Torres, Vincente E.
TI  - REPRISE 3b Study in Enrollment Phase
DP  - 2015 Feb 01
TA  - MD Conference Express
PG  - 14--14
VI  - 14
IP  - 49
4099  - http://mdc.sagepub.com/content/14/49/14.short
4100  - http://mdc.sagepub.com/content/14/49/14.full
AB  - Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease in adults and is the fourth-leading cause of end-stage renal disease. The Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease [REPRISE 3b; NCT02160145] study's objective is to compare the efficacy of tolvaptan, a selective arginine vasopressin V2 receptor antagonist, with placebo in adults with ADPKD. Results are discussed in this article.